Progyny/$PGNY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
- Ticker
- $PGNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 846
- Headquarters
- New York, United States
- Website
- www.progyny.com
Progyny Metrics
BasicAdvanced
$2.2B
32.18
$0.91
0.99
-
Price and volume
Market cap
$2.2B
Beta
0.99
52-week high
$33.07
52-week low
$16.10
Average daily volume
1M
Financial strength
Current ratio
2.137
Quick ratio
2.059
Long term debt to equity
0.05
Total debt to equity
0.05
Profitability
EBITDA (TTM)
125.572
Gross margin (TTM)
24.57%
Net profit margin (TTM)
6.00%
Operating margin (TTM)
9.14%
Effective tax rate (TTM)
34.38%
Revenue per employee (TTM)
$1,550,000
Management effectiveness
Return on assets (TTM)
10.14%
Return on equity (TTM)
16.24%
Valuation
Price to earnings (TTM)
32.18
Price to revenue (TTM)
1.839
Price to book
4.95
Price to tangible book (TTM)
5.24
Price to free cash flow (TTM)
13.515
Free cash flow yield (TTM)
7.40%
Free cash flow per share (TTM)
2.16
Growth
Revenue change (TTM)
5.54%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
22.78%
What the Analysts think about Progyny
Analyst ratings (Buy, Hold, Sell) for Progyny stock.
Analyst projections of the future price of Progyny stock.
Bulls say / Bears say
Progyny says its 2027 selling season could bring 1.2 million new covered lives, a potential record that would support future growth if the expected decisions convert. (GlobeNewswire)
Underlying demand is growing: second-quarter revenue rose 11% after excluding the former client’s prior-year contribution, and the client count increased to 604 from 542. (GlobeNewswire)
Profitability improved faster than sales in the second quarter: gross margin rose to 25.5% from 23.7%, while net income increased to $28.1 million from $17.1 million. (GlobeNewswire)
The loss of a major client remains a drag and shows the risk of relying on large accounts: reported second-quarter revenue growth was 5.3%, versus 11% excluding that former client’s prior-year revenue. (GlobeNewswire)
Pharmacy benefits grew only 1.2% in the second quarter, well behind fertility services at 7.6%, leaving growth increasingly reliant on the fertility business. (GlobeNewswire)
Employer budget pressure can delay new business, and some prospects favour capped reimbursement plans instead of Progyny’s broader offering, which could slow customer wins. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Progyny Financial Performance
Revenues and expenses
Progyny Earnings Performance
Company profitability
Upcoming events
No upcoming events
Progyny News
AllArticlesVideos
Funds containing Progyny
AllUSDEURGBP
Fund name | Fund size | $PGNY weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.12% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.